ANZICS CTG Endorsed Study
Perioperative dexmedetomidine in high risk cardiac surgery evaluation
This is a multinational double blind randomised placebo controlled evaluation of peri-operative dexmedetomidine starting at induction of anaesthesia.
Population: Adults undergoing cardiac surgery with eGFR < 60 ml/min OR undergoing a combined or complex aortic surgery. Exclusion criteria include salvage surgery, eGFR < 15 ml/min, dialysis dependent, extracorporeal support.
Sample size: 2600 patients. Stratified at randomisation according to eGFR lower or higher than 60 ml/min.
Intervention: Dexmedetomidine 0.7 mcg/kg/hour starting at induction of anaesthesia. Continued at 0.35 mcg/kg/hr till 24 hours after surgery or as clinically desirable. Comparator: Placebo infusion.
Outcome: MAKE90 = death + dialysis + persistent AKI at day 90.
Yahya Shehabi (Chair), Michael Bailey, Rinaldo Bellomo, Lauren Bulfin, Z Endre, John Fraser, Belinda Howe, Shay McGuinness, Rachael Parke, David Scott, Julian Smith and Steve Webb.
ANZIC Research Centre, Monash University
Monash University, ANZCA Clinical Trials Network
Project Status as of June 2019
Preparation work has commenced.
Yahya Shehabi (email)